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Cancer of the uterine cervix, following breast cancer, is the second leading cause of death among gy-
necological cancers in the developed world. Traditionally, surgical management of early-stage cervical
carcinoma is considered as a “sterilizing” procedure, since the uterus is removed. Nowadays, because of
the postponement of childbearing to an older age, women younger than 45 years old who are diagnosed
with early-stage cervical cancer have a strong desire to preserve fertility. Radical trachelectomy (vaginal
or abdominal route) is used for fertility preservation in cases of early-stage (International Federation of
Gynecology and Obstetrics Stages IAeIB1) cervical carcinomas with remarkable oncological and
obstetrical outcomes. However, less radical approaches for ideal candidates may prove safe when fertility
preservation is probably feasible.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Cancer of the uterine cervix holds the third place among the
most common cancers in women worldwide. Approximately
12,360 women with invasive cervical cancer are newly diagnosed
each year, and about one-third of them die from this disease [1].
Although the average patient age at diagnosis is 48e50 years,
20e22% of cervical cancer cases are diagnosed in women younger
than 39 years [2]. Even in the developed world with organized
screening programs for cervical cancer, although cervical cancer is
frequently diagnosed at an early stage, the percentage of women
suffering from the disease remains high [3].
The International Federation of Gynecology and Obstetrics
(FIGO) deﬁnes early-stage cervical cancer as FIGO Stage IAeIB1
disease. Currently, for patients with cervical cancer at FIGO Stages
IA2eIB1, adequate treatment is based on radical surgery with or
without subsequent radiotherapy, depending on the presence of
pathologic risk factors such as tumor size, parametrial invasion,
lymph nodemetastasis, positive surgical margins, and deep stromaltrics and Gynecology, Gyne-
iversity of Athens, Alexandra
8, Greece.
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bstetrics & Gynecology. Published binvasion. However, radical surgery does not spare fertility and the
potential of childbearing is eliminated. Therefore, due to the post-
ponement of childbearing to an older age, women younger than
45 years who are diagnosed with cervical carcinoma have a strong
desire to preserve fertility [4]. A radical surgery may lead to psy-
chosexual dysfunction, depression, grief, stress, and decreased
quality of life. Moreover, signiﬁcant emotional and physical impacts
may be observed [5,6]. Since the number of younger patients who
are diagnosed with cancer and plan on a future pregnancy has
increased, the gynecological oncology community has recently
revised the radical surgical philosophy in order to preserve fertility,
maintaining an excellent oncological outcome, without increasing
the risk of recurrence.
Less radical surgery for early-stage cervical cancer
Revolutionary treatment for early-stage cervical cancer was
ﬁrst presented in 1994 [7], supporting the concept that the
uterine body, and consequently fertility potential, could safely be
preserved in well-selected cases. Radical vaginal trachelectomy
was later described as removal of cervix, parametrium, and cuff
of the vagina with maintenance of the uterine fundus and
adnexae. Radical vaginal trachelectomy combined with laparo-
scopic pelvic lymphadenectomy was considered as the appro-
priate fertility sparing approach for early-stage cervical cancer.y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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many surgeons were more familiar with this procedure due to its
similarities with radical abdominal hysterectomy [8]. However,
the abdominal approach results in a wider parametrial dissection
than the vaginal route, and it is debatable if this extensive sur-
gery is required for Stage IA2 disease. By contrast, the abdominal
procedure could lead to pelvic adhesion formation, which may
add to future fertility difﬁculties. There has been a speculation in
the community of obstetricians and gynecologists about the
radical treatment of the disease, and over the years the radicality
has been abandoned and more conservative techniques have
been developed. Initially, there was skepticism about the new
procedures; however, the philosophy of conservative surgery has
gradually been established, and radical trachelectomy has
emerged as a valuable therapeutic method for preserving fertility
in young women with early-stage cervical cancer. In recent years,
two other methods, laparoscopic and robotic-assisted radical
trachelectomy, have been developed. Each procedure has ad-
vantages and disadvantages based on the different abilities of the
surgeon performing the procedure and the available technical
equipment. Up to now, several authors have reported on the
safety and efﬁcacy of these two procedures, demonstrating both
the obstetrical and the oncological outcomes [9e12].
Multiple studies supported the safety and efﬁcacy of radical
trachelectomy [13e15]. In addition, retrospective studies have
shown that there is no signiﬁcant difference in the oncologic out-
comes between traditional radical hysterectomy and radical tra-
chelectomy [16]. However, it is almost universally accepted that
radical trachelectomy should not be offered to patients with
tumors  2 cm in size due to the high rate of relapses (12.5%) [17].Selection criteria
The current literature supports that conservative management
of cervical carcinoma is primarily addressed in women with low-
risk early-stage disease. It is of utmost importance to recognize
suitable candidates and manage them in an appropriate way.
Most importantly, the strong desire of patients for fertility
preservation should be considered, and womenwho do not wish to
preserve their fertility may be excluded. Tumor size is one of the
most important factors responsible for recurrence. Lesions larger
than 2 cm in size involves a higher risk of recurrence: 12.5% versus
1.2% for lesions < 2 cm in size [17]. The histological type of the
cancer should also be taken into account, as squamous cell,
adenocarcinoma, and adenosquamous carcinoma are acceptable for
radical trachelectomy, while small-cell neuroendocrine carcinoma
is not suitable, because it has the worst prognosis due to its asso-
ciation with lymph node metastasis, local/distant relapse, and a
need for postoperative chemotherapy.Radical surgery morbidity
Radical surgery, due to extensive parametrial resection, is
accompanied by a high rate of morbidity. Nerve injury, bladder and
bowel dysfunction, sexual dysfunction that may appear as dyspar-
eunia, decreased arousal, and decreased swelling are considerably
increased.
These problems have a signiﬁcant impact not only on the sexual
life of women, but on their psychology as well, since they lose their
interest, are unsatisﬁed, or suffer from anxiety regarding inter-
course [18]. Although the transaction of the uterine arteries poses a
high risk for future fertility, there are pregnancies and term births,
after uterine artery ligation conﬁrming the successful utero-ovarian
circulation [8].Philosophy of less radical surgery
In recent years, removal of the parametria has been revised due
to the morbidity associated with parametrectomy, taking into ac-
count the risk factors for recurrence after radical trachelectomy,
such as tumor size > 2 cm, positive lymphovascular space
involvement (LVSI), and tumor inﬁltration depth > 10 mm [17]. For
patients with tumor size < 2 cm, negative pelvic lymph nodes, and
inﬁltration depth < 10 mm, the risk of parametrial involvement is
about 0.6% [19]. Parametrial spread is a strong predictor of recur-
rence and decreased survival. Parametrial invasion is rare (< 0.4%)
in patients with small tumors, no LVSI, and negative pelvic nodes
[20]. For the above reasons, radical procedures in patients with a
tumor size of < 2 cm are considered as overtreatment. Frumovitz
et al [21], in their study of 300 women, found that the rate of
parametrial involvement was almost zero.
Our view of early-stage cervical cancer treatment is in agree-
ment with that of the supporters of less radical procedures. We
recently supported the fact that less radical surgery is possible in
patients with Stage IB1 cervical cancer. Patients with a depth of
inﬁltration of  13 mm and negative lymph nodes represent a
subgroup with a very low risk for parametrial spread (< 0.7%).
These patients could be considered for less radical surgery such as
cervical conization or simple hysterectomy with pelvic lymphade-
nectomy, in order to minimize morbidity related with radical
removal of the cervix and optimize the obstetric outcome. In
conclusion, our study conﬁrmed the low incidence of parametrial
involvement (< 0.7%) in early-stage cervical cancerd< 2 cm in
length, < 13 mm in depth of inﬁltration, and negative pelvic lymph
nodesdas suggested in previous studies [22]. The data compiled
from different studies showed a rate of < 1% for parametrial
involvement in patients with low-risk characteristics of cervical
cancer. These results demonstrate that patients with early-stage
cervical cancer are candidates for less radical surgery [23]. There-
fore, we identiﬁed a group of patients at low risk for parametrial
disease who may be candidates for omission of parametrectomy
and can be safely cured by a less radical surgery, as already
mentioned in the literature.
Neoadjuvant chemotherapy
The role of neoadjuvant chemotherapy (NACHT) in the treat-
ment of early-stage cervical cancer is under investigation. Typical
indications for NACHT are to reduce tumor size in order to later
facilitate radical surgical resection, as well as minimize prognostic
factors that are associatedwith a poor response such as lymph node
metastasis, LVSI, and parametrial involvement, thereby eliminating
the need for postoperative adjuvant radiotherapy. Although recent
literature describes many different chemotherapeutic regimens
and dosages (cisplatin, carboplatin, paclitaxel, mitomycin, vincris-
tine, bleomycin, mitomycin, 5-ﬂouoracil, ifosfamide, etc.), the most
commonly used chemotherapy agents are cisplatin (50 g/m2),
vinblastine (1 mg/m2 on Days 1 and 2), and bleomycin (25 mg/m2
for 3 days) for two to four cycles. The response to chemotherapy is
monitored with magnetic resonance imaging or computed to-
mography [1,24]. In some patients, there has been no evidence of
residual disease in surgical specimens following NACHT. Many au-
thors recommend the use of NACHT prior to the surgery to
downstage tumors >2 cm, in order to follow more conservative
cervical resection, diminishing the risk of relapse and improving
obstetrical results [24]. Nonetheless, the majority of trials found
that the role of NACHT in early-stage cervical cancer is not unam-
biguous, and therefore it should not be used outside of clinical trial
protocols. More studies are needed in order to determine the
oncological safety of the procedure as well as the obstetrical
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pregnancy rate appeared to be higher for patients with
tumors  2 cm in size who underwent NACHT followed by con-
servative surgery (30.6%), compared with those who underwent
immediate Vaginal Radical Trachelectomy (VRT) (24%) or abdom-
inal radical trachelectomy (16.5%).
Sentinel lymph node mapping
Lymph node status reﬂects parametrial invasion and lymph node
metastasis is considered an important prognostic factor for recur-
rence of cervical cancer, impacting both treatment decisions and
patient clinical outcomes. Although complete pelvic lymphade-
nectomy is obligatory, lymph node status is not included in the
classiﬁcation of staging according to the FIGO. Although approxi-
mately 15% of early-stage cervical cancer is complicated with lymph
node metastasis and the survival rate for these patients is expected
to be adequate since disease response to treatment is satisfactory,
apparently a large proportion of patients may undergo an extensive
surgerywith no direct beneﬁt and be exposed to the potential risk of
additional morbidity accompanying a wide lymphadenectomy.
Sentinel lymph node (SLN) mapping as part of the surgical
management of selected stage cervical cancer is nowadays rec-
ommended in gynecological oncology practices worldwide. An SLN
is deﬁned as the ﬁrst lymph node to which cancer cells are most
likely to spread from a primary tumor. Sometimes, there can be
more than one SLN. SLN biopsy/ultrastaging is then followed in
order to identify the SLN removed and examined to determine
possible micrometastasis. A negative SLN biopsy result suggests
that cancer has not developed the ability to spread to nearby lymph
nodes or other tissues. A positive SLN biopsy result indicates that
cancer is present in the SLN and may be present elsewhere. This
information may alter postoperative management.
Ongoing prospective trials
Three large prospective trials are currently evaluating the role of
more conservative procedures in patients with low-risk early-stage
cervical carcinoma. A large multicenter prospective trial (ConCerv)
is evaluating the safety and expediency of the conservative
approach in women with the disease and appropriate selection
characteristics. This trial includes patients with Stage IA2eIB1
disease, with the size of tumor being 2 cm or smaller. Patients who
wish to preserve their childbearing ability are treated more
conservativelywith cone excision and pelvic lymph node dissection
including SLN mapping. Women not desiring fertility are treated
with simple hysterectomy and pelvic lymphadenectomy [23].
Another largemulticenter prospective cohort study (GOG-0278),
led by Alan Covens, is designed to evaluate the physical function and
quality of life before and after nonradical surgical therapy (extra-
fascial hysterectomy or cone biopsy with pelvic lymphadenectomy)
for Stage IA1 (LVSIþ) and IA2eIB1 ( 2 cm) cervical cancer [25].
Finally, a randomized trial (Shape trial), led by Marie Plante,
compared radical hysterectomy and pelvic node dissection with
simple hysterectomy and pelvic node dissection in patients with
low-risk early-stage cervical cancer. The recruited population
includewomenwithStage IA2or IB1andGrade1, 2, or 3diseasewith
squamous or adenocarcinoma histological type and tumor size
< 2 cm, and < 10 mm stromal invasion on Loop Electrosurgical
Excision Procedure (LEEP)/cone biopsy [26].
Our belief
Up to now, nonradical surgery for the treatment of early-stage
cervical cancer seems to be a safe and effective option in well-selected patients. Although cone biopsy alone is commonly
applied for Stage IA1 squamous cell carcinoma of the cervix
without LVSI, where the risk of pelvic nodal disease is approxi-
mately 1% and the recurrence rate is very low, the use of cone bi-
opsy in Stage >IA1 tumors is controversial given the high risk of
nodal involvement when depth of inﬁltration is > 3 mm. Therefore,
it is mandatory to consider pelvic lymph node dissection in this
group of patients. To this point, many studies [27e39] support the
oncological safety of cone biopsy and pelvic lymphadenectomy in
Stage  IA2 uterine cervical carcinoma. It is believed that this
approach could be considered for young women demanding
fertility preservation since obstetrical outcomes may be safer and
more effective compared with trachelectomy.
Since lymph node status reﬂects parametrial invasion, the
question that arises is whetherwe could omit parametrial resection
in women with early-stage cervical cancer, tumor size <2 cm, and
negative lymph nodes. Given the fact that parametrial tissue may
hide microscopic spreading of multifocal disease, we believe that
this metastatic disease in the remaining parametrium (after cone
biopsy in Stage >IA1 squamous cell carcinoma of the cervix with
LVSI) could cause pelvic recurrences if not excluded during surgical
exploration. In addition, the risk of pelvic lymph node involvement
in Stage IA2 is approximately 8%, while the risk of lymphovascular
space invasion is 33% and subsequent recurrence may reach 4%.
Therefore, lymphadenectomy should always be considered in these
cases. After all, is any possibility for less than less radical surgery
without affect the oncological outcome? Multicentric prospective
randomized studies are necessary to deﬁne the most favorable and
appropriate management with regard to both the selection of pa-
tients and the appropriate surgical approach. More obstetrical
outcomes need to be published based on the number of pregnan-
cies achieved after nonradical treatments.
Conclusively, less radical approaches for ideal candidates may
prove safe when fertility preservation is requested. Careful selec-
tion of patients remains the hallmark of success.
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